Nivolumab and Stereotactic Radiosurgery for Patients With Breast Cancer Brain Metastases: A Nonrandomized, Open-Label Phase 1b Study

Nivolumab and Stereotactic Radiosurgery for Patients With Breast Cancer Brain Metastases: A Nonrandomized, Open-Label Phase 1b Study

Purpose: We hypothesize treatment with nivolumab and stereotactic radiosurgery (SRS) will be feasible and well tolerated, and may improve intracranial tumor control rates compared with SRS alone. Methods and Materials: The study was designed as a prospective, single-arm, nonrandomized, open-label, p...

Full description

Bibliographic Details
Main Authors: Kamran A. Ahmed, MD, Youngchul Kim, PhD, John A. Arrington, MD, Sungjune Kim, MD, PhD, Michelle DeJesus, BS, Aixa E. Soyano, MD, Avan J. Armaghani, MD, Ricardo L.B. Costa, MD, Hung T. Khong, MD, Loretta S. Loftus, MD, Marilin Rosa, MD, Jimmy J. Caudell, MD, PhD, Roberto Diaz, MD, PhD, Timothy J. Robinson, MD, PhD, Arnold B. Etame, MD, PhD, Nam D. Tran, MD, PhD, Solmaz Sahebjam, MD, Hatem H. Soliman, MD, Brian J. Czerniecki, MD, PhD, Peter A. Forsyth, MD, H. Michael Yu, MD, Hyo S. Han, MD
Format: Article
Language:English
Published: Elsevier 2021-11-01
Series:Advances in Radiation Oncology
Online Access:http://www.sciencedirect.com/science/article/pii/S2452109421001561

Internet

http://www.sciencedirect.com/science/article/pii/S2452109421001561

Similar Items